| Outcome Measures: |
Primary: Coronary microvascular function, The changes in coronary flow velocity reserve at 12 weeks compared to baseline in the active drug/placebo groups, From enrollment to the end of treatment at 12 weeks | Secondary: Cardiopulmonary exercise capacity (VO2peak, mL/min/kg), The changes in cardiopulmonary exercise capacity ((VO2peak, mL/min/kg) at 12 weeks compared to baseline in the active drug/placebo groups, From enrollment to the end of treatment at 12 weeks|Body weight (kg), Changes in body weight (kg) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Systolic and diastolic blood pressure (mmHg), Changes in Systolic and diastolic blood pressure (mmHg) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Waist circumference (cm), Changes in waist circumference (cm) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Lipid profile, Changes in total cholesterol (mg/dL), triglycerides (mg/dL), high-density lipoprotein cholesterol (mg/dL), and low-density lipoprotein cholesterol (mg/dL) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Hemoglobin A1c (%), Changes in hemoglobin A1c (%) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|NT-proBNP (pg/mL), Changes in NT-proBNP (pg/mL) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Self-assessment of sarcopenia (score), Changes in self-assessment of sarcopenia (score) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|5-time chair rise test (sec), Changes in 5-time chair rise test (sec) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Body composition analysis - skeletal muscle mass index, Changes in skeletal muscle mass index (kg/m2) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Body composition analysis - visceral fat area, Changes in visceral fat area (cm2) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Echocardiographic findings - chamber size (mm), Changes in chamber size (mm) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Echocardiographic findings - ejection fraction (%), Changes in ejection fraction (%) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Echocardiographic findings - E/e', Changes in E/e' at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks|Echocardiographic findings - global longitudinal strain (%), Changes in global longitudinal strain (%) at 12 weeks compared to baseline, From enrollment to the end of treatment at 12 weeks
|
